Progen to Present Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
2007 NOV 19 -- Progen Pharmaceuticals Limited (NASDAQ:PGLA) announced that Dr. James Garner, Progen's Vice President of Clinical and Medical Affairs will present a poster entitled "The Interactive Effect of Prognostic Factors and PI-88 Use on the Delay of HCC Recurrence Following Curative Partial Hepatic Resection" at the 58th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, USA(1) on Saturday, 3 November 2007. The poster presentation will be made available on Progen's website http://www.progen-pharma.com/ from approximately 9am (Brisbane time) Saturday 3 November 2007. (1) Each year, the American Association for the Study of Liver Diseases brings together over 6,000 hepatologists and hepatology health professionals from around the world for its annual meeting to meet and exchange the latest liver disease research, and discuss treatment outcomes. Keywords: Hepatic Resection, Liver Cancer, Liver Carcinoma, Liver Disease, Oncology, Pharmaceuticals, Progen Pharmaceuticals Limited. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
